Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms

Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms
CVRx tallies 15th Barostim implant

CVRx announced that Dr. Philip Seibel and the team at Lawnwood Medical Center have successfully completed their 15th Barostim implant.

This milestone reflects sustained efforts to provide innovative therapy options for patients with heart failure. Barostim therapy is designed to improve patient outcomes by targeting cardiovascular health through advanced implant technology. CVRx continues to support medical teams in their adoption and deployment of new solutions for chronic conditions.

CVRx previously presented Barostim device therapy at ACC26, highlighting its aim to improve exercise capacity for heart failure patients beyond standard GDMT here. The company also forecast preliminary Q1 2026 revenue between $14.7 million and $14.8 million, projecting 20 percent growth from the prior year period here. These developments reflect CVRx’s ongoing expansion of both its clinical innovations and financial footprint.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.